NASDAQ:CTKB
Cytek Biosciences, Inc.
Cytek Biosciences, Inc.'s revenue grew 0.5% in fiscal 2025 to $201.5M while operating margin fell to −20.0%. Free cash flow was −$8.8M, −4.4% of revenue, and the diluted share count fell 2.2%.Summary generated from Cytek Biosciences, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$201.5M
Revenue growth+0.5%
Revenue, 5-yr CAGR+209.5%
Gross margin51.8%
Operating margin−20.0%
Net margin−33.0%
ROICn/a
Return on equity−18.0%
Debt / equityn/a
Free cash flow−$8.8M
FCF margin−4.4%
Share count change−2.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 | 3 | 193 | 200 | 201 |
| Operating income | 9 | −2 | −28 | −21 | −40 |
| Net income | 3 | 2 | −12 | −6 | −67 |
| Free cash flow | 0 | −22 | 1 | 22 | −9 |
Recent filings
- 8-KAmendment to articles or bylaws
Sep 29, 2026 - 8-KRegulation FD disclosure
Aug 24, 2026 - 4Insider transaction report
Aug 20, 2026 - 4Insider transaction report
Aug 20, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KDirector or officer change
Jul 15, 2026 - 8-KDirector or officer change
Jun 25, 2026